These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20095134)

  • 1. Adenosine A2A receptor antagonists as novel anti-Parkinsonian agents: a review of structure-activity relationships.
    Azam F; Ibn-Rajab IA; Alruiad AA
    Pharmazie; 2009 Dec; 64(12):771-95. PubMed ID: 20095134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.
    Shah U; Hodgson R
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
    Dowling JE; Vessels JT; Haque S; Chang HX; van Vloten K; Kumaravel G; Engber T; Jin X; Phadke D; Wang J; Ayyub E; Petter RC
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4809-13. PubMed ID: 16153830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.
    Gillespie RJ; Cliffe IA; Dawson CE; Dourish CT; Gaur S; Giles PR; Jordan AM; Knight AR; Lawrence A; Lerpiniere J; Misra A; Pratt RM; Todd RS; Upton R; Weiss SM; Williamson DS
    Bioorg Med Chem Lett; 2008 May; 18(9):2920-3. PubMed ID: 18407496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Chen L; Zhang J; Petter RC
    J Med Chem; 2004 Aug; 47(17):4291-9. PubMed ID: 15294001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.
    Gillespie RJ; Adams DR; Bebbington D; Benwell K; Cliffe IA; Dawson CE; Dourish CT; Fletcher A; Gaur S; Giles PR; Jordan AM; Knight AR; Knutsen LJ; Lawrence A; Lerpiniere J; Misra A; Porter RH; Pratt RM; Shepherd R; Upton R; Ward SE; Weiss SM; Williamson DS
    Bioorg Med Chem Lett; 2008 May; 18(9):2916-9. PubMed ID: 18406614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.
    Vu CB; Pan D; Peng B; Sha L; Kumaravel G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Petter RC
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4831-4. PubMed ID: 15341933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and synthesis of novel adenosine receptor (A(2A)) antagonists.
    Matasi JJ; Caldwell JP; Hao J; Neustadt B; Arik L; Foster CJ; Lachowicz J; Tulshian DB
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1333-6. PubMed ID: 15713381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A
    Rohilla S; Bansal R; Kachler S; Klotz KN
    Bioorg Chem; 2019 Jun; 87():601-612. PubMed ID: 30933785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Pan D; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Petter RC
    J Med Chem; 2005 Mar; 48(6):2009-18. PubMed ID: 15771443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
    Vu CB; Shields P; Peng B; Kumaravel G; Jin X; Phadke D; Wang J; Engber T; Ayyub E; Petter RC
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4835-8. PubMed ID: 15341934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the design and optimization of adenosine A2A receptor antagonists.
    Vu CB
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):458-68. PubMed ID: 16022182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.
    Van der Walt MM; Terre'Blanche G; Petzer A; Lourens AC; Petzer JP
    Bioorg Chem; 2013 Aug; 49():49-58. PubMed ID: 23892098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
    Peng H; Kumaravel G; Yao G; Sha L; Wang J; Van Vlijmen H; Bohnert T; Huang C; Vu CB; Ensinger CL; Chang H; Engber TM; Whalley ET; Petter RC
    J Med Chem; 2004 Dec; 47(25):6218-29. PubMed ID: 15566292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.